-
AIDS Interview | HIV Vaccine: Where Are We Now, and What Does the Future Hold?
01 IIDF: How would you assess the current progress in HIV vaccine development? Are we nearing the realization of an effective and widely available HIV vaccine? Dr Sok: Yes, this…
-
New Advances in Renal Cancer Treatment
Excited to share this insightful talk with Dr. Liangyou Gu on tackling clear cell renal cell carcinoma with innovative approaches like neoadjuvant toripalimab. The future of kidney cancer treatment is evolving, and these advancements are offering real hope for better outcomes. Watch the video for key highlights!
-
Impact of Gut Microbiota on Patients with Decompensated Cirrhosis
The research included 75 participants: 45 with decompensated cirrhosis (LC group) and 30 healthy controls (C group). Patients in the LC group exhibited elevated serum levels of ALT, TBIL, PT,…
-
ESMO 2024 丨 Dr. Trevor Leong: The TOPGEAR study confirms that preoperative radiotherapy cannot prolong long-term survival in resectable gastric cancer
In the past, there has been ongoing debate about the therapeutic value of radiotherapy in resectable gastric cancer. The TOPGEAR study presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) evaluated the comparison between preoperative chemoradiotherapy and perioperative chemotherapy alone. Dr. Trevor Leong, the Principal Investigator from the University of…
-
Dr. Yelena Janjigian: The DESTINY-Gastric03 study confirms the therapeutic prospect of the T-DXd triple regimen in HER2-positive
The DESTINY-Gastric03 study (abstract number 14010), presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona), evaluated the efficacy and safety of T-DXd combined with FP and anti-PD-1 as first-line treatment for adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJA). At the conference site, we specially invited the Principal Investigator,…
-
ESMO 2024丨 Dr. Benoit You interprets the TROPHAMET trial: 96% of low-risk gestational trophoblastic tumors can be eradicated
At the 2024 ESMO annual meeting, Benoit You from the Lyon Sud Hospital Center, France, presented the results of the phase I/II TROPHAMET trial (abstract number 711O) in the preferred oral report session and was interviewed by Oncology Frontier.
-
Insights from Professor Nicolaus Kroger on Advancing Myelofibrosis Treatment
In a groundbreaking discussion, Professor Nicolaus Kroger delves into the evolving landscape of allogeneic stem cell transplantation for myelofibrosis. Learn how post-transplant monitoring and strategic donor T cell activity enhancements…
-
ESMO 2024丨Dr. Junyuan Qi: Cutting Through the Fog, Promising Phase I Results for the New BCL-2 Inhibitor in R/R NHL and AML
From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world’s top oncology conferences, it brought together experts and scholars from across the globe to share cutting-edge research findings and discuss future directions. At the session dedicated to hematologic malignancies, Dr.…
Connecting Medical Expertise through Media